Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB06 vs Norditropin FlexPro in pediatric growth hormone deficiency
ChiCTR2600122736Phase 3Not yet recruiting
- Sponsor
- Chengdu Women's and Children's Central Hospital
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Chengdu Women's and Children's Central Hospital. Primary endpoint: Annualized height velocity at week 52. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on ChiCTR2600122736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122736.